Global Bioengineered protein drugs Market Size study & Forecast, by Drug Type( Recombinant Protein Drugs, Peptide Hormones, Vaccines, Therapeutic Enzymes, Monoclonal Antibodies, Cytokines and Others) by Disease ( Diabetes, Cancer, Skin Diseases , Blood d

Global Bioengineered protein drugs Market Size study & Forecast, by Drug Type( Recombinant Protein Drugs, Peptide Hormones, Vaccines, Therapeutic Enzymes, Monoclonal Antibodies, Cytokines and Others) by Disease ( Diabetes, Cancer, Skin Diseases , Blood disorders, Heart Diseases, Neurodegenerative Diseases and Others), by Technology (Fractionation, Bioreactors And Microbial Cell Fermentation, Genetic Engineering, Genetically Modified Organisms, Pharming and Others), by Drug Delivery Method (Traditional Methods, Novel approaches according to recent research) and Regional Analysis, 2022-2029

Global Bioengineered protein drugs Market is valued approximately USD XX billion in 2021 and is anticipated to grow with a healthy growth rate of more than XX% over the forecast period 2022-2029. Bioengineered proteins, which serve as potent therapeutic proteins, are created to be essential participants in all biological processes. These unique medications are attracting interest from the pharmaceutical industry due to their specificity, safety, bio reactivity, and success rate in treating serious illnesses and injuries. Drugs made from bioengineered proteins are key players in the biological process and the development of effective therapeutics. The medication made from bioengineered proteins contains a variety of items, including hormones, vaccines, cytokines, and monoclonal antibodies. The Bioengineered protein drugs market is expanding because of factors such as rising prevelance of various diseases such as cancer, diabetes and other diseases as well as rising development of personalized medicine.

Rising prevelance of cancer globally is fostering the market growth, , according to estimates from the International Agency for Research on Cancer (IARC), there were 17.0 million new instances of cancer and 9.5 million cancer-related deaths in 2018 and it is estimated increase to 27.5 million new cases by 2040. One of the chronic diseases with the quickest rate of growth is diabetes. In recent decades, its prevalence has steadily increased. The World Health Organization projects that by 2021, diabetes will affect 537 million individuals worldwide, with one in ten developing other forms of the disease. Moreover, populations that are elderly and fat are more likely to develop chronic diseases. The World Bank Group estimates that there were 727 million senior citizens worldwide in 2020, and that number will triple over the next three decades, reaching 1.5 billion by 2050. In addition, rising drug discovery activities, and rising healthcare research and development activities in the region is fostering the market growth. However, the high cost of Bioengineered protein drugs stifles market growth throughout the forecast period of 2022-2029.

The key regions considered for the Global Bioengineered protein drugs Market study includes Asia Pacific, North America, Europe, Latin America, and Rest of the World. North America dominated the market in terms of revenue, owing to the dominance of branded products and the region's increasing disease prevalence. Whereas Asia Pacific is expected to grow with a highest CAGR during the forecast period, owing to factors such as rising geriatric and target populations, an increase in the number of collaborations for product development, geographic expansion of key players, and active participation of government and nonprofit organizations in the market space.

Major market player included in this report are:
Abbott Laboratories
Amgen
Baxter Healthcare
Bayer Healthcare Pharmaceuticals
Eli Lilly And Co.
GlaxoSmithKline
Hoffman-la-Roche
Johnson And Johnson
Merck And Co. Inc.,
Fresenius Kabi USA

Recent Developments in the Market:
In April 2022, Satellite Bio introduces a fresh method for creating tissues using bioengineering. This company has expertise in synthetic biology, regenerative medicine, cell therapy, cell biology, and tissue engineering.
In January 2022, A new biotechnology company named Altos Laboratories was founded with the goal of deciphering the intricate biology underlying the cellular renewal programming.

Global Bioengineered protein drugs Market Report Scope:
Historical Data 2019-2020-2021
Base Year for Estimation 2021
Forecast period 2022-2029
Report Coverage Revenue forecast, Company Ranking, Competitive Landscape, Growth factors, and Trends
Segments Covered Drug Type, Diseases, Technology, Drug Delivery Methods, Region
Regional Scope North America; Europe; Asia Pacific; Latin America; Rest of the World

The objective of the study is to define market sizes of different segments & countries in recent years and to forecast the values to the coming years. The report is designed to incorporate both qualitative and quantitative aspects of the industry within countries involved in the study.

The report also caters detailed information about the crucial aspects such as driving factors & challenges which will define the future growth of the market. Additionally, it also incorporates potential opportunities in micro markets for stakeholders to invest along with the detailed analysis of competitive landscape and Drug Typeofferings of key players.

The detailed segments and sub-segment of the market are explained below:

By Drug Type:
Recombinant Protein Drugs
Peptide Hormones
Vaccines
Therapeutic Enzymes
Monoclonal Antibodies
Cytokines
Others

By Disease:
Diabetes
Cancer
Skin Diseases
Blood disorders
Heart Diseases
Neurodegenerative Diseases
Others
By Technology:
Fractionation
Bioreactors And Microbial Cell Fermentation
Genetic Engineering
Genetically Modified Organisms
Pharming
Others

By Region:
North America
U.S.
Canada
Europe
UK
Germany
France
Spain
Italy
ROE
Asia Pacific
China
India
Japan
Australia
South Korea
RoAPAC
Latin America
Brazil
Mexico
RoLA
Rest of the World

Companies Mentioned

Abbott Laboratories
Amgen
Baxter Healthcare
Bayer Healthcare Pharmaceuticals
Eli Lilly And Co.
GlaxoSmithKline
Hoffman-la-Roche
Johnson And Johnson
Merck And Co. Inc.,
Fresenius Kabi USA

Please note:The single user license is non-downloadable and non-printable. Global Site license allows these actions. Show more